Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome

Obesity Clinical Trial

Official title:

The Efficacy of Irvingia Gabonensis (Bush Mango) in the Management of Overweight, Obesity and Metabolic Syndrome in Cameroon.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00645775
• Other study ID #: GHAIGOB131CT
• Status: Completed
• Phase: N/A
• First received: March 25, 2008
• Last updated: March 25, 2008
• Start date: November 2006
• Est. completion date: April 2007

Study information

• Verified date: August 2006
• Source: Gateway Health Alliance
• Contact: n/a
• Is FDA regulated: No
• Health authority: Cameroon: Ministry of Public Health
• Study type: Interventional

Clinical Trial Summary

The study investigated the use and efficacy of the seeds of African bush mango (Irvingia gabonensis)to control body weight, blood lipids and hormones in overweight and obese people.

Description:

To assess the effects of seeds of Irvingia gabonensis on body weight, fasting blood glucose, plasma total and LDL cholesterol in 102 overweight and obese participants.

The study was a 10 week randomized, double blind, placebo controlled design. participants were randomly divided into 2 groups of 51 participants each. Group 1 was the placebo group, while Group 2 was the active group. Each group received 2 daily doses of 125 mg (before meals) of either placebo or Irvingia gabonensis.

Weight as well as fasting blood was taken at baseline and at 4, 8 and 10 weeks. No major detary changes or exercises were suggested during the study period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 102
• Est. completion date: April 2007
• Est. primary completion date: March 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 19 Years to 50 Years

Eligibility

Inclusion Criteria:

• BMI>26

Exclusion Criteria:

• Diabetics Pregnant and lactating Participating in any other weight reducing program Smokers

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dyslipidemia
• Dyslipidemias
• Metabolic Syndrome
• Metabolic Syndrome X
• Obesity
• Syndrome

Intervention

Dietary Supplement:
• IGOB131
Comparison of 250 mg per day of Irvingia gabonensis to placebo

Locations

Country	Name	City	State
Cameroon	Laboratory of Nutrition & Nutritional Biochemistry	Yaounde	Centre

Sponsors (2)

Lead Sponsor	Collaborator
Gateway Health Alliance	University of Yaounde

Country where clinical trial is conducted

Cameroon, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weight change		10 weeks	No
Secondary	Change in blood lipids and hormone levels		10 weeks	No